Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladarixin and Sotorasib in Advanced KRAS G12C Mutant NSCLC
NCT05815186Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ladarixin in non-small cell lung cancer (NSCLC), sponsored by NYU Langone Health. Planned start Apr 2024; status: withdrawn.
02
Drugs
ladarixin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05815186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815186.